YWYizhuo Wang

Yizhuo Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yizhuo Wang has a total of 43 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Phase 1b study of ABBV-744, a novel, selective BET inhibitor, as monotherapy for patients with myelofibrosis

    by John O. Mascarenhas, Laura Maria Fogliatto, Steven D Green, Ignacio Corvalan, Elie Traer, Keita Kirito, Hun S Chuah, Kazuki Sakatoku, Rasmus T. Hoeg, Mohamad Khawandanah, et al.

    Janus kinase inhibitors (JAKi) are standard of care for patients with myelofibrosis (MF) but can be associated with treatment-limiting cytopenias and do not modify underlying disease. Novel treatments targeting other clinically relevant pathways are needed. Inhibitors of bromodomain (BD) and extraterminal domain (BET) proteins are a promising class of drugs that have demonstrated the ability to modulate key pathways involved in inflammation, fibrosis, and apoptosis. ABBV-744 is a novel small molecule that targets the BDII of BET proteins and has previously been shown to be well tolerated when administered daily at doses of 120 and 180 mg to patients with acute myeloid leukemia. We report the outcomes of a multicenter, open-label phase 1b study of ABBV-744 in patients with MF who received ≥1 previous lines of therapy, including a JAKi. The primary objective was safety, including dose-limiting toxicities (DLTs). Secondary end points included a reduction in spleen volume of ≥35% (SVR35), ≥50% reduction in total symptom score (TSS50), objective response rate, and pharmacokinetics. All 21 patients experienced at least 1 treatment-emergent adverse event, and 11 patients experienced a DLT. The most common events leading to DLTs were thrombocytopenia (33%) and anemia (24%). SVR35 was attained in 24% of patients at week 12 and 33% at week 24. TSS50 was reported for 29% of patients at 12 weeks and 19% at week 24. These outcomes are noteworthy in this heavily pretreated population considering the advanced disease state and limited treatment options for this patient population. This trial was registered at www.clinicaltrials.gov as NCT04454658.


  • Open Access

    τ$\tau$‐Inflated Beta Regression Model for Estimating τ$\tau$‐Restricted Means and Event‐Free Probabilities for Censored Time‐to‐Event Data

    by Yizhuo Wang, Susan Murray

    In this research, we propose analysis of ‐restricted censored time‐to‐event data via a ‐inflated beta regression (‐IBR) model. The outcome of interest is , where and are the time‐to‐event and follow‐up duration, respectively. Our analysis goals include estimation and inference related to ‐restricted mean survival time (‐RMST) values and event‐free probabilities at that address the censored nature of the data. In this setting, it is common to observe many individuals with , a point mass that is typically overlooked in ‐restricted event‐time analyses. Our proposed ‐IBR model is based on a decomposition of into . We model the mean of this latter expression using joint logistic and beta regression models that are fit using an expectation‐maximization algorithm. An alternative multiple imputation (MI) algorithm for fitting the ‐IBR model has the additional advantage of producing uncensored datasets for analysis. Simulations indicate excellent performance of the ‐IBR model(s), and corresponding ‐RMST estimates, in independent and dependent censoring settings. We apply our method to the Azithromycin for Prevention of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations Trial. In addition to ‐IBR model results providing a nuanced understanding of the treatment effect, visually appealing heatmaps of the ‐restricted event times based on our MI datasets are given, a visualization not typically available for censored time‐to‐event data.

  • Association between CFTR modulators and changes in iron deficiency markers in cystic fibrosis

    by Shijing Jia, Yizhuo Wang, Melissa H Ross, Jonathan B Zuckerman, Susan Murray, MeiLan K Han, Shannon E Cahalan, Blair E Lenhan, Ryan N Best, Jennifer L Taylor-Cousar, et al.


  • Open Access

    τ$ \tau $‐Inflated beta regression model for censored recurrent events

    by Yizhuo Wang, Susan Murray

    This research introduces a multivariate tau-inflated beta regression (tau-IBR) modeling approach for the analysis of censored recurrent event data that is particularly useful when there is a mixture of (a) individuals who are generally less susceptible to recurrent events and (b) heterogeneity in duration of event-free periods amongst those who experience events. The modeling approach is applied to a restructured version of the recurrent event data that consists of censored longitudinal times-to-first-event in tau length follow-up windows that potentially overlap. Multiple imputation (MI) and expectation-solution (ES) approaches appropriate for censored data are developed as part of the model fitting process. A suite of useful analysis outputs are provided from the tau-IBR model that include parameter estimates to help interpret the (a) and (b) mixture of event times in the data, estimates of mean tau-restricted event-free duration in a tau-length follow-up window based on a patient's covariate profile, and heat maps of raw tau-restricted event-free durations observed in the data with censored observations augmented via averages across MI datasets. Simulations indicate good statistical performance of the proposed tau-IBR approach to modeling censored recurrent event data. An example is given based on the Azithromycin for Prevention of COPD Exacerbations Trial.


  • Consideration of stratification in confirmatory trials with time-to-event endpoint

    by Yizhuo Wang, Xuan Zhou, Zifang Guo, Xiao Fang, Fang Liu, Liji Shen


  • Open Access

    Fibrotic Lung Disease Alters Neutrophil Trafficking and Promotes Neutrophil Elastase and Extracellular Trap Release

    by Helen I Warheit-Niemi, Gabrielle P. Huizinga, Summer J. Edwards, Yizhou Wang, Susan K. Murray, David N. O’dwyer, Bethany B. Moore

    Idiopathic pulmonary fibrosis (IPF) is a progressive, irreversible disease characterized by collagen deposition within the interstitium of the lung. This impairs gas exchange and results in eventual respiratory failure. Clinical studies show a correlation between elevated neutrophil numbers and IPF disease progression; however, the mechanistic roles neutrophils play in this disease are not well described. In the present study, we describe alterations to the trafficking and function of neutrophils after the development of fibrosis. We observed increased numbers of total and aged neutrophils in peripheral tissues of fibrotic mice. This appeared to be driven by an upregulation of neutrophil chemokine Cxcl2 by lung cells. In addition, neutrophil recruitment back to the bone marrow for clearance appeared to be impaired, because we saw decreased aged neutrophils in the bone marrow of fibrotic mice. Neutrophils in fibrosis were activated, because ex vivo assays showed increased elastase and extracellular trap release by neutrophils from fibrotic mice. This likely mediated disease exacerbation, because mice exhibiting a progressive disease phenotype with greater weight loss and mortality had more activated neutrophils and increased levels of extracellular DNA present in their lungs than did mice with a nonprogressive disease phenotype. These findings further our understanding of the dynamics of neutrophil populations and their trafficking in progressive fibrotic lung disease and may help inform treatments targeting neutrophil function for patients with IPF experiencing disease exacerbation in the future.